Li-Ying Wang, Jian-Yuan Tang, Jun Liu, Wei Lu, Ya-Nan Yu, Bi-Wei Chen, Hong-Li Wu, Li-Ya Su, Zhi-Wei Jing, Si-Yuan Hu, Xiang-Ling Liu, Xi-Yan Yang, Guo-Xin Li, Bo Dong, Dong-Hai Wang, Jie Xue, Xiao-Feng Wang, Zhuo-Ming Li, Shu-Rong Liu, Song-Shan Liu, Qi-guang Chen, Lei Zhang, Zhong Wang, Chun-Ti Shen and Yong-Yan Wang Pages 492 - 503 ( 12 )
Objective: To reveal the cutoff point and influencing factors in the dynamic change in phenotypic group in patients with stable angina pectoris (SAP) after Xinxuekang capsule treatment.
Methods: Five hundred and seventy-six SAP patients were randomly assigned to receive Xinxuekang (XXK) capsules or Compound Danshen (CDS) tablets for 8 weeks. Global similarity degree analysis and nonlinear mixed effects modeling (NONMEM) were employed to reveal the cutoff points and influencing factors in dynamic changes in the SAP phenotypic group. The phenotypic group was defined as the six phenotypes in SAP, including angina, choking sensation in the chest, palpitations, dark purple lips, ecchymosis on the tongue, and fine-choppy pulse, which were quantitatively evaluated on Days 0, 14, 28, 42, and 56.
Results: Variation in the six individual phenotypes and distribution of the SAP phenotypic profile were similar between the two experimental groups, but cutoff points for changes in the SAP phenotypic group were 7.28 and 10.73 weeks in XXK and CDS groups, respectively. Degree of severity of SAP as well as study site significantly affected the tendency for change in the SAP Xueyu Zheng in both XXK and CDS treatment groups. Different Chinese patent drugs affected the tendency for change in phenotypic group in patients with SAP. XXK was superior to CDS in controlling a clinical phenotypic group.
Conclusion: Based on global similarity degree analysis and NONMEM, the cutoff point and influencing factors in phenomic variation of SAP may be determined, to improve the development and modification of treatment regimens.
Stable angina pectoris, similarity degree analysis, nonlinear mixed effect model, treatment effectiveness.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Dongzhimennei Nanxiaojie 16#, Beijing 100700, China.